Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
|
|
|
- Margery Clarke
- 6 years ago
- Views:
Transcription
1 Page 1 of 6 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ [ % $ bil 12.3 mil 12.7 mil Stock Price XNYS:MRK: % 2018 Morningstar s Take Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, Merck is through... Key Stats Stock Ind Avg Price/Earnings TTM Price/Book Price/Sales TTM Rev Growth (3 Yr Avg) Net Income Growth (3 Yr Avg) Operating Margin % TTM Net Margin % TTM ROA TTM ROE TTM Debt/Equity Financials Fair Value Estimate $ Consider Buying $ Consider Selling $ Fair Value Uncertainty Low Economic Moat Wide Stewardship Standard Growth C Profitability C Morningstar Credit Rating Relative to Industry - Avg + Annual Quarterly Income Statement Revenue 39,807 39,498 42,237 10,325 10,536 Operating Income 6,030 6,928 5, ,070 Net Income 3,920 4,442 11, ,184 Earnings Per Share Shares Outstanding 2,787 2,841 2,928 2,727 2,786 Balance Sheet Current Assets 30,614 29,764 33,173 27,919 29,440 Non Current Assets 64,763 72,015 65,162 63,757 68,895 Total Assets 95, ,779 98,335 91,676 98,335 Current Liabilities 17,204 19,203 18,766 19,467 15,555 Total Liabilities 55,289 57,103 49,688 53,428 54,591 Stockholders' Equity 40,088 44,676 48,647 38,248 43,744 Dividends Declared Date 28/11/2017 Ex-Dividend Date 14/12/2017 Latest Indicated Dividend Amount 0.48 Projected Yield 3.28 % Recent Dividends & Type Amount Splits 12/14/2017 Cash Dividends /14/2017 Cash Dividends /13/2017 Cash Dividends /13/2017 Cash Dividends Competitors Name Price % Chg TTM Sales $ mil Merck & Co Inc $ [ 39,804 Johnson & Johnson $ [ 74,361 Roche Holding AG Dividend Right Cert. $ [ 55,916 Pfizer Inc $ [ 52,471 Novartis AG ADR $ [ 50,135 Novartis AG $ [ 50,135 Recommendations Current 4.4 Total Analysts: Buy Hold Sell Ownership Fund Owners Star Rating % Shares Held % Total Assets IG/GWL Dividend GIF QQQ /75 B Investors US Large Cap QQ Value A Investors Canadian Large QQ Cap Value A RBC QUBE Low Volatility QQQ US Eq Ser FT5 RBC QUBE US Equity Series O Insiders % Change TTM % Shares Outstanding Kenneth C. Frazier 77, Roger M. Perlmutter 34, Mirian M. Graddick-weir -16, Robert M. Davis Michael J. Holston -12, Cash Flow Cash From Operations 10,376 12,421 7,860-1,171 2,971 Capital Expenditures -1,614-1,283-2,
2 Morningstar Analyst Rating. Page 2 of 6 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ [ % $ bil 12.3 mil 12.7 mil Financials Annual Quarterly Free Cash Flow 8,762 11,138 5,543-1,612 2,562 In millions except "EPS". Currency in USD.
3 Page 3 of 6 Industry Classification NAICS Pharmaceutical Preparation Manufacturing (325412) SIC Pharmaceutical and Medicine Industry (3741);Pharmaceutical Preparations (2834) ISIC Manufacture of Pharmaceuticals, Medicinal Chemical and Botanical Products (2100) Operation Details Fiscal Year Ends CIK Year Established Employees (31/12/2016) Full Time Part Time Auditor (31/12/2016) PricewaterhouseCoopers LLP Legal Advisor (31/12/2009) McCarter & English, LLP Key Executives Kenneth C. Frazier/Chairman of the Board, President and Chief Executive Officer; Roger M. Perlmutter/Executive Vice President and President, Merck Research Laboratories; Mirian M. Graddick-Weir/Executive Vice President, Human Resources; Robert M. Davis/Executive Vice President and Chief Financial Officer; Michael J. Holston/Executive Vice President and General Counsel; Julie L. Gerberding/Executive Vice President, Strategic Communications, Global Public Policy and Population Health; Sanat Chattopadhyay/Executive Vice President and President, Merck Manufacturing Division; Richard R. Deluca/Executive Vice President and President, Merck Animal Health; Adele D. Ambrose/Senior Vice President and Chief Communications Officer; Rita A. Karachun/Senior Vice President, Finance, Global Controller and Principal Accounting Officer; Adam H. Schechter/Executive Vice President and President, Global Human Health Company Profile Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. 30-day Avg Volume Market Cap Net Income Sales Sector Industry Stock Style Direct Investment Dividend Reinvestment 13.9Mil 159.5Bil 2.8Bil 39.8Bil Healthcare Drug Manufacturers - Major 1 Large Value Yes Yes
4 Page 4 of 6 Industry Peers Morningstar Rating Market Cap $Mil Net Income $Mil P/S P/B P/E Dividend Yield% 5 Yr Rev CAGR% Med Oper. Margin% Interest Coverage Merck & Co Inc QQQQ 163,084 2, Johnson & Johnson (USD) QQ 376,166 15, Pfizer Inc (USD) QQQQ 219,532 9, Novartis AG (USD) QQQ 207,760 7, Novartis AG (USD) 207,760 7, Roche Holding AG (USD,CHF) 205,219 9, Roche Holding AG (USD,CHF) QQQQQ 205,219 9, Roche Holding AG (USD,CHF) 205,219 9, AbbVie Inc (USD) QQ 185,728 6, Sanofi SA (USD,EUR) QQQQ 109,125 9, Sanofi SA (USD,EUR) 109,125 9, Bayer AG (USD,EUR) 106,238 7, Bayer AG (USD,EUR) QQQQ 106,238 7, Bristol-Myers Squibb Company (USD) QQQ 102,784 4, GlaxoSmithKline PLC (USD,GBP) QQQQ 92,194 2, GlaxoSmithKline PLC (USD,GBP) 92,194 2, Eli Lilly and Co (USD) QQQ 90,741 2, AstraZeneca PLC (USD) QQ 87,565 3, AstraZeneca PLC (USD) 87,565 3, AstraZeneca PLC (USD) 87,565 3, Chugai Pharmaceutical Co Ltd (USD,JPY) 29,956 67, Chugai Pharmaceutical Co Ltd (USD,JPY) 29,956 67, Astellas Pharma Inc (USD,JPY) 27, , Astellas Pharma Inc (USD,JPY) 27, , Otsuka Holdings Co Ltd (USD,JPY) 24,768 57, Otsuka Holdings Co Ltd (USD,JPY) 24,768 57, Daiichi Sankyo Co Ltd (USD,JPY) 23,222 38, Daiichi Sankyo Co Ltd (USD,JPY) 23,222 38, CSPC Pharmaceutical Group Ltd (USD,HKD) 14,171 2, Ono Pharmaceutical Co Ltd (USD,JPY) 11,747 53, Ono Pharmaceutical Co Ltd (USD,JPY) 11,747 53, Kyowa Hakko Kirin Co Ltd (USD,JPY) 11,070 21, Recordati (USD,EUR) 9, Santen Pharmaceutical Co Ltd (USD,JPY) 6,830 25, Santen Pharmaceutical Co Ltd (USD,JPY) 6,830 25, PT Kalbe Farma Tbk (USD,IDR) 5,900 2,376, PT Kalbe Farma Tbk (USD,IDR) 5,900 2,376, Alfresa Holdings Corp (USD,JPY) 5,519 31, Hutchison China Meditech Ltd (USD) 4, Hutchison China Meditech Ltd (USD) 4, GW Pharmaceuticals PLC (USD,GBP) 3, GW Pharmaceuticals PLC (USD,GBP) 3, Dechra Pharmaceuticals PLC (USD,GBP) 2, Aerie Pharmaceuticals Inc (USD) 2, Cosmo Pharmaceuticals NV (USD,EUR) 2, Tong Ren Tang Technologies Co Ltd (USD,CNY) 2, Haw Par Corp Ltd (USD,SGD) 2, Haw Par Corp Ltd (USD,SGD) 2, Boiron SA (USD,EUR) 1, United Laboratories International Holdings Ltd (USD,CNY) 1, D/E
5 Page 5 of 6 Industry Peers Zogenix Inc (USD) 1, Virbac SA (USD,EUR) 1, TherapeuticsMD Inc (USD) 1, Retrophin Inc (USD) Vectura Group PLC (USD,GBP) Vetoquinol SA (USD,EUR) Mayne Pharma Group Ltd (USD,AUD) Torii Pharmaceutical Co Ltd (USD,JPY) 803 3, Shandong Luoxin Pharmaceutical Group Stock Co Ltd ,394.3 (USD,CNY) Tempo Scan Pacific Tbk (USD,IDR) , Eco Animal Health Group PLC (USD,GBP) AB Science (USD,EUR) Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (USD,CNY) Rockwell Medical Inc (USD) Allergy Therapeutics PLC (USD,GBP) Daiken Medical Co Ltd (USD,JPY) 215 1, SymBio Pharmaceuticals Ltd (USD,JPY) 105-3, ,357.2 Opthea Ltd (USD,AUD) Opthea Ltd (USD,AUD) Oasmia Pharmaceutical AB (USD,SEK) , Alimera Sciences Inc (USD) PhotoCure ASA (USD,NOK) Pharmaxis Ltd (USD,AUD) Moberg Pharma AB (USD,SEK) Futura Medical PLC (USD,GBP) ,274.6 Nanoviricides Inc (USD) Tonix Pharmaceuticals Holding Corp (USD) ProPhase Labs Inc (USD) Innovus Pharmaceuticals Inc (USD) NeuroVive Pharmaceutical AB (USD,SEK) , , Avivagen Inc (USD,CAD) , China Pharma Holding Inc (USD) Sunwin Stevia International Inc (USD) Alliqua BioMedical Inc (USD) Immune Pharmaceuticals Inc (USD) , Biostar Pharmaceuticals Inc (USD) Antisense Therapeutics Ltd (USD,AUD) Aoxing Pharmaceutical Co Inc (USD) Integrated Biopharma Inc (USD) Enzyme Bio Systems (USD) ,320.8 Echo Therapeutics Inc (USD) , ,445.6 Tongli Pharmaceuticals (USA) Inc (USD) Enzymes American Holding Corp Cell Tech International Inc (USD) Skystar Bio-Pharmaceutical Co (USD) Canopus Biopharma Inc JinZangHuang Tibet Pharmaceuticals Inc (USD) GFR Pharmaceuticals Inc (USD) Global Pharmatech Inc (USD) Somatic Systems Inc Emerging World Pharma Inc InterNatural Pharmaceuticals Inc
6 Page 6 of 6 Industry Peers Neurogenesis Inc Pharmaconnect Inc Innovative Holdings Alliance Inc Endocan Corp (USD) Genex Pharmaceutical Inc (USD) Laxai Pharma Ltd (USD) Hubei Minkang Pharmaceutical Ltd (USD) China Health Resource Inc (USD) Kun Run Biotechnology Inc (USD) Merck Tbk (USD,IDR) 157, Alfresa Holdings Corp (USD,JPY) 31, Winston Pharmaceuticals Inc (USD) Nouveau Life Pharmaceuticals Inc (USD) Nutrastar International Inc (USD) AtheroNova Inc (USD) Biotie Therapies Corp (USD,EUR) Bohai Pharmaceuticals Group Inc (USD) Star Nutrition Inc Adia Nutrition Inc Shandong Luoxin Pharmaceutical Group Stock Co Ltd (USD,CNY) ,394.3 Nichi-Iko Pharmaceutical Co Ltd (USD,JPY) 5, Cipla Ltd (USD,INR) 11, Dong Xin Bio-Tech Pharmaceutical Inc Dawnrays Pharmaceutical (Holdings) Ltd (USD,CNY) ,123.9 Artec Inc NV Global Green Inc (USD) Beximco Pharmaceuticals Ltd (USD,BDT) 2, Torrent Pharmaceuticals Ltd (USD,INR) 8, Piramal Enterprises Ltd (USD,INR) 14, GlaxoSmithKline Pharmaceuticals Ltd (USD,INR) 3, , Il Yang Pharmaceutical Co Ltd (USD,KRW) 4, Xi An 38 Fule Health & Advisory Co Ltd Pierrel SpA (USD,EUR) Whanin Pharm Co Ltd (USD,KRW) 22, Shandong Xinhua Pharmaceutical Co Ltd (USD,CNY) Mayne Pharma Group Ltd (USD,AUD) Kyowa Hakko Kirin Co Ltd (USD,JPY) 21, Industry Average 37,268 52, , ,
CenterPoint Energy Inc CNP
Page 1 of 5 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 28.86 [-0.15-0.52 % $ 28.97 28.66-28.97
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 5 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 65.46 ]0.14 0.21 % $ 65.35 64.85-66.05
RGC Resources Inc RGCO
Morningstar Analyst Rating Page 1 of 5 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 27.08 [-0.88-3.15 % $ 27.71 27.00-27.85
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Morningstar Analyst Rating Page 1 of 5 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 47.65 [-0.40-0.83 % $ 47.95 47.65-48.65
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Morningstar Analyst Rating Page 1 of 5 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 52.70 [-0.70-1.31 % $ 53.55 52.10-53.85
Stora Enso Oyj ADR SEOAY
Morningstar Analyst Rating Page 1 of 5 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 16.13 ]0.21 1.32 % $ 16.15 16.12-16.15
National Grid PLC ADR NGG
Page 1 of 5 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 57.57 ]0.42 0.73 % $ 57.40 57.21-57.68
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 5 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 9.18 [-0.01-0.11 % $ 9.10 9.10-9.22 7.04-10.31
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Morningstar Analyst Rating Page 1 of 5 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF [ % - 0.00-0.00 mil -- Stock Price 2017-01-02-2017-08-03
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 5 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 136.10 ]0.07 0.05 % $ 136.62 135.78-136.63
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 5 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 83.76 ]2.11 2.58 % $ 82.16 81.74-83.90
Tanger Factory Outlet Centers Inc SKT
Morningstar Analyst Rating Page 1 of 5 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 22.94 ]0.12 0.53 % $ 22.93 22.26-23.03
Kimco Realty Corp KIM
Page 1 of 5 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 14.31 [-0.21-1.45 % $ 14.41 14.25-14.52
EQM Technologies & Energy Inc EQTE
Morningstar Analyst Rating Page 1 of 6 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 0.02 ]0.00 5.00 % $ 0.02 0.02-0.02 0.01-0.05
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 5 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 169.23 [-1.85-1.08 % $ 170.52 169.22-170.59
Anheuser-Busch InBev SA/NV ADR BUD
Page 1 of 5 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 111.76 [-2.34-2.05 % $ 112.82 111.18-112.87
LDK Solar Co Ltd ADR LDKYQ
Morningstar Analyst Rating Page 1 of 5 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 0.03 ]0.00 14.28 % $ 0.02 0.02-0.03 0.00-0.04
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 5 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 50.69 ]1.67 3.41 % $ 49.19 48.87-50.88
Concordia International Corp CXR
Morningstar Analyst Rating Page 1 of 5 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 0.72 ]0.02 3.45 % $ 0.70 0.69-0.73 0.46-2.97
Microchip Technology Inc MCHP
Page 1 of 6 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 85.16 ]1.24 1.48 % $ 84.81 83.67-85.22
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 5 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 46.23 ]0.23 0.50 % $ 46.00 45.94-46.36
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 6 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 43.30 ]0.22 0.51 % $ 43.35 43.11-43.58
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 6 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 66.47 ]0.44 0.67 % $ 66.04 65.50-66.60
United Technologies Corp UTX
Page 1 of 6 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 127.57 [-0.55-0.43 % $ 128.32 127.57-128.49
International Business Machines Corp IBM
Page 1 of 7 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 155.41 ]0.60 0.39 % $ 154.97 154.57-155.89
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 6 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 265.88 ]0.73 0.28 % $ 265.26 264.53-266.57
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 5 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 18.50 ]0.38 2.07 % $ 18.50 18.43-18.65
Background Distribution and Safety Issues in the United States Consumer Advertising/Promotion World Health and Life Expectancy
CHAPTER ONE: EXECUTIVE SUMMARY Background Scope and Methodology Size and Growth of the Market Key Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION Background Distribution
Transparency guidelines and disclosure payments in the pharmaceutical industry
Transparency guidelines and disclosure payments in the pharmaceutical industry Abstract Based on the Transparency Guidelines for the Relationship between Corporate Activities and Medical Institutions established
Investors Global Health Care Class
Interim Management Report of Fund Performance FOR THE SIX-MONTH PERIOD ENDED SEPTEMBER 3, 17 CAUTION REGARDING FORWARD-LOOKING STATEMENTS This report may contain forward-looking statements about the Fund,
Market Capitalization $374.3 Billion
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F Annual Dividend Rate BUY BUY RATING SINCE 03/30/2012 TARGET PRICE $161.28 BUSINESS DESCRIPTION Johnson & Johnson, together with its subsidiaries,
PPH VanEck Vectors Pharmaceutical ETF
VanEck Vectors Pharmaceutical ETF ETF.com segment: Equity: Global Pharmaceuticals Competing ETFs: GNRX Related ETF Channels: Pharmaceuticals, Healthcare, Vanilla, Global, Equity, Sectors Find more ETFs
Tyson Foods Inc Class A TSN
Page 1 of 7 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 82.85 ]1.57 1.93 % $ 81.48 81.48-83.03
Raiffeisen HealthCare Equities
(Original German name: Raiffeisen-HealthCare-Aktien) Semi-annual fund report 2013 Table of contents General fund information... 3 Fund characteristics... 3 Legal notice... 4 Fund details... 5 Units in
Measuring the return from pharmaceutical innovation 2017 Methodology
Measuring the return from pharmaceutical innovation 2017 Methodology Contents Introduction 01 Methodology 02 Original cohort 03 Extension cohort 03 Assets evaluated 03 Methodology amendments and restatements
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 8 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 66.51 ]0.35 0.53 % $ 66.37 66.04-67.05
Archer-Daniels Midland Co ADM
Page 1 of 7 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 40.26 ]0.07 0.17 % $ 40.22 40.17-40.50
Global Blood Therapeutics Inc GBT
Global Blood Therapeutics Inc GBT Page 1 of 5 Last Close Fair Value Q Market Cap Industry of Domicile 29 Nov 217 3 Nov 217 2: UTC 29 Nov 217 37.4 36.84 1,634.4 Mil d Healthcare Biotechnology USA United
National Oilwell Varco Inc NOV
Page 1 of 8 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 37.71 ]0.11 0.29 % $ 37.80 37.40-37.95
Acadia Pharmaceuticals. Daniel Berrios, Xianming Li, Ryan Matsumoto, Sunny Huang, Kojo Osei, Ariana Bhatia
Acadia Pharmaceuticals Daniel Berrios, Xianming Li, Ryan Matsumoto, Sunny Huang, Kojo Osei, Ariana Bhatia Introduction: ACAD Acadia Pharmaceuticals ACAD Small cap, relatively young, bio pharmaceutical
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 7 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 66.74 [-0.25-0.37 % $ 66.90 66.55-67.43
SAMPLE. Pharmaceuticals
Data as of Market Close: 29 December 2017 Industry Outlook Pharmaceuticals Industry Leaders & Laggards Report Comparable analysis, for companies or transactions, must be conducted against an industry background.
Legal & General Global Health & Pharmaceuticals Index Trust. Interim Manager s Report for the period ended 14 July 2011 (Unaudited)
Legal & General Global Health & Pharmaceuticals Index Trust Interim Manager s Report for the period ended 14 July 2011 (Unaudited) Contents Page Number Manager s Investment Report 2 Authorised Status
Market Capitalization $7.6 Billion. Weekly Price: (US$) SMA (50) SMA (100) 1 Year 2 Years
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F Annual Dividend Rate BIO BUSINESS DESCRIPTION Bio-Rad Laboratories, Inc. manufactures and supplies products and systems to separate complex chemical
Invesco V.I. Health Care Fund Quarterly Schedule of Portfolio Holdings September 30, 2018
Quarterly Schedule of Portfolio Holdings September 30, 2018 invesco.com/us I-VIGHC-QTR-1 11/18 Invesco Advisers, Inc. Schedule of Investments (a) September 30, 2018 (Unaudited) Shares Value Common Stocks
Healthcare Sector The Stock Market SIM, Professor West. Yiping Yang, Lu Yu
Healthcare Sector The Stock Market SIM, Professor West Yiping Yang, Lu Yu 1 Agenda Sector Overview Business and Economic Analysis Financial Analysis Valuation Analysis Recommendation 2 Sector Overview
Prof. Claude Farrugia Vice President Communications, EIPG
Prof. Claude Farrugia Vice President Communications, EIPG Is the storm over? Malta, 2008 Is the storm over? Malta, 2008 Is the storm over? Malta, 2008 Drug Development is Risky Drug Development is a Costly
Healthcare Leaders Income Fund. Healthcare Leaders Income Fund. Annual Financial Statements
Healthcare Leaders Income Fund Annual Financial Statements December 31, 2015 MANAGEMENT RESPONSIBILITY FOR FINANCIAL REPORTING The accompanying financial statements have been prepared by Harvest Portfolios
Market Capitalization $6.3 Billion
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F Annual Dividend Rate BUY SDAQ: ICLR BUY RATING SINCE 03/26/2013 TARGET PRICE $151.83 ICLR BUSINESS DESCRIPTION ICON Public Limited Company, a contract
COMPANY PRESENTATION - HEALTHCARE. Anthony Rogers, Thomas Rosol & Dylan Seymour
COMPANY PRESENTATION - HEALTHCARE Anthony Rogers, Thomas Rosol & Dylan Seymour Agenda Overview Business Analysis Financial Analysis Valuation Analysis Company Analysis Recommendation 2 S&P 500 Sector Weight
Foreign Direct Investment in the Health Care Sector in Developing Countries Locations and Governance
Foreign Direct Investment in the Health Care Sector in Developing Countries Locations and Governance J. François Outreville UNCTAD, Division on Investment, Technology and Enterprise Development 1 FDI and
XPH SPDR S&P Pharmaceuticals ETF
SPDR S&P ETF ETF.com segment: Equity: U.S. Competing ETFs: IHE, PJP, FTXH Related ETF Channels: Sectors, Healthcare, Equal-Weighted, U.S., Smart-Beta ETFs, Equity, North America, Find more ETFs with our
Market Capitalization $112.8 Billion
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F BUY November 19, 2017 BUY RATING SINCE 04/25/2017 TARGET PRICE $56.90 SNY BUSINESS DESCRIPTION Sanofi researches, develops, manufactures, and markets
Sterling Pfizer Inc. Biotech Limited. 03 June 2009 Initiation Report. Wyeth acquisition to support Pfizer after losing patent for Lipitor RATING: BUY
Initiation Report Wyeth acquisition to support Pfizer after losing patent for Lipitor RATING: BUY Target price (6-24 month): US$18.76 Reuters ticker: PFE Bloomberg ticker: PFE US Analyst: Nishith Sanghvi
AFTERSHOCKS. Benjamin Tal, Managing Director, Deputy-Chief Economist CIBC World Markets Inc. Will Investment in Renewable Energy Follow Oil Prices?
, Managing Director, Deputy-Chief Economist CIBC World Markets Inc 67 th Annual Tax Conference 67e Conférence fiscale annuelle 2 Will Investment in Renewable Energy Follow Oil Prices? Source: UNEB, CIBC
Indian Pharmaceutical Formulations Industry Report,
Indian Pharmaceutical Formulations Industry Report, 2008-2009 India plays an important role in the global pharmaceutical market. In 2005, 2/5 DMFs to FDA were submitted by India. Currently, there are more
INSTITUTIONAL RESEARCH Biotechnology COMPANY UPDATE Member FINRA/SIPC
INSTITUTIONAL RESEARCH Biotechnology COMPANY UPDATE Member FINRA/SIPC Toll Free: 561-391-5555 www.dawsonjames.com 1 North Federal Highway - Suite 500 Boca Raton, FL 33432 OncoSec Medical (Nasdaq/ONCS)
Pharmaceuticals - Generics
Q3: Quarterly Industry Update AS OF September 30, 2017 Pharmaceuticals - Generics INDUSTRY SUMMARY COGENT VALUATION identified Pharmaceuticals - Generics publicly traded companies, IPOs, and recent M&A
Fidelity Global Health Care Fund
Fidelity Global Health Care Fund Semi-Annual Management Report of Fund Performance September 3, Caution Regarding Forward-looking Statements Certain portions of this report, including, but not limited
Sunoco, Inc. SUN [NYSE]
![Sunoco, Inc. SUN [NYSE]](/thumbs/91/104511352.jpg "Sunoco, Inc. SUN [NYSE]")
? Sunoco, Inc. SUN [NYSE] High oil prices and a weak consumer environment should translate into lower margins for Sunoco. heavy sour crude discounts will remain strong; consequently, the financial performance
$100,000,000 (Maximum) Up to 4,000,000 Preferred Shares and 4,000,000 Class A Shares $10.00 per Preferred Share and $15.00 per Class A Share
No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. This prospectus constitutes a public offering of these securities only in those
CIF Stock Recommendation Report (Spring 2014)
Date: 27 February 2014 Analyst Name: Hayden Wieck & Connor McCulloh CIF Stock Recommendation Report (Spring 2014) Company Name and Ticker: Bristol-Myers Squibb (BMY) Section (A) Investment Summary Recommendation
CIF Stock Recommendation Report (Fall 2012)
Section (A) Summary CIF Stock Recommendation Report (Fall 2012) Recommendation: Do Not Buy Recommended Buy Price: $69 Sector: Industrials Company Name and Ticker: Caterpillar Inc. (CAT) Industry: Farm
M&A 1H17 Review China Pharmaceutical Sector
www.pwccn.com M&A 1H17 Review China Pharmaceutical Sector Agenda Foreword Overview Strategic Buyers Financial Buyers Mainland China Outbound Deals 2 Foreword Explanation of data presented in this report
Remuneration Report Roche 121. Remuneration Report. Material topics covered in this chapter. Executive remuneration
120 Remuneration Report Roche 121 Remuneration Report Material topics covered in this chapter Executive remuneration 122 1. Principles Compensation policy: roche.com/rewards Sound value system: roche.com/living_
Your Medicines Supply Chain toolkit. Your NPA. Equipping you to survive and thrive
Your Medicines Supply Chain toolkit Your NPA Equipping you to survive and thrive Abbott Diabetes 6% 5% 0% + 6% Nutritional ZD ZD 0% Other X X 0% + 6% Abbvie X X 0% Actavis - Warner Chilcott 5.5% 6% X AHA
Indian Active Pharmaceutical Ingredients (APIs) Industry Report,
Indian Active Pharmaceutical Ingredients (APIs) Industry Report, 2008-2009 India plays an important part in the global API market. The API output value of India was US $4.1 billion in 2007, with the CAGR
XLV Health Care Select Sector SPDR Fund
Health Care Select Sector SPDR Fund ETF.com segment: Equity: U.S. Health Care Competing ETFs: VHT, IYH, FHLC, PSCH, FXH Related ETF Channels: North America, U.S., Healthcare, Broad-based, Vanilla, Equity,
SIM GLOBAL EQUITY INCOME FUND
SIM GLOBAL EQUITY INCOME FUND DOUW STEENEKAMP The appointed investment manager of the SIM Global Equity Income Fund is Denker Capital, a division of Sanlam Investment Management (Pty) Ltd, an authorised
CIF Sector Recommendation Report (Spring 2013)
Date: 4/1/2013 Analyst: Jacob Allen CIF Sector Recommendation Report (Spring 2013) Sector: Healthcare Review Period: 3/13/2013 3/26/2013 Section (A) Sector Performance Review Copy/paste Sector Review Spreadsheet
$ Novo Nordisk A/S Sponsored ADR Class B. Grade 68.6
Grade Earnings Last Earnings Release 11/01/2017 Last Qtr. Actual vs. Est. $0.62 / $0.61 Next Release 11/02/2017 $0.61 Year Ending 12/31/2016 $2.17 Quick Facts Dividend Yield 1.48% 52 Wk High $55.04 52
Morningstar Stock Report. Carter's CRI. 2 Quote/Snapshot 3 Analyst Report 5 Financials 6 Valuation 7 Ownership
Morningstar Stock Report 2 Quote/Snapshot 3 Analyst Report 5 Financials 6 Valuation 7 Ownership Release date 21 Mar 2007 NASD Members: For internal use or client reporting purposes only Page 2 of 7 Quote/Snapshot
PT. Kalbe Farma Tbk.
9/29/2017 10/29/2017 11/29/2017 12/29/2017 1/29/2018 2/28/2018 3/31/2018 4/30/2018 5/31/2018 6/30/2018 7/31/2018 8/31/2018 Equity Research 28 September 2018 Consumer Goods PT. Kalbe Farma Tbk. Investment
The shifting balance of firepower
January 2014 Perspectives from the EY Global Life Sciences Center Firepower Index and Growth Gap Report 2014 EY s Global Life Sciences Center is dedicated to offering relevant insights and industry leadership
CIF Stock Recommendation Report (Fall 2012)
Section (A) Summary CIF Stock Recommendation Report (Fall 2012) Company Name and Ticker: Boeing BA Recommendation Buy: Yes Target Price: $83.00 Sector: Industrials Industry: Aerospace & Defense Market
Quick counterattack on rival
GILEAD SCIENCES - BUY Quick counterattack on rival This company was selected on the basis of Jyske Quant. Jyske Quant is a model that rates companies based on a string of factors. In that way, the model
LARGE CAP VALUE STRATEGY
LARGE CAP VALUE STRATEGY P V G A S S E T M A N A G E M E N T March 31 st 2017 L O S S A V E R S E I N V E S T I N G W W W. P V G A S S E T M A N A G E M E N T. C O M Content About PVG 3 Philosophy & Process
Dr Reddy Laboratories Ltd RDY (XNYS)
Morningstar Equity Analyst Report Report as of 06 Nov 2015 Page 1 of 10 Morningstar Pillars Analyst Quantitative Economic Moat Narrow Narrow Valuation QQ Overvalued Uncertainty High Low Financial Health
ResMed Inc. RMD [XNYS] QQQ
![ResMed Inc. RMD [XNYS] QQQ](/thumbs/91/107702935.jpg "ResMed Inc. RMD [XNYS] QQQ")
? ResMed Inc. RMD [XNYS] QQQ ResMed's execution continues to impress, but growth prospects are priced in. so ResMed must continue to stay ahead of the pack on innovation to prevent price erosion from substantially
Evolve Global Healthcare Enhanced Yield ETF
Interim Report June 30, 2018 Evolve Global Healthcare Enhanced Yield ETF TSX: LIFE www.evolveetfs.com Table of Contents: Page Interim Management Discussion of Fund Performance 3 Summary of Investment Portfolio
HIKMA PHARMACEUTICALS PLC UBS GLOBAL GENERIC & SPECIALITY PHARMACEUTICALS CONFERENCE NEW YORK 8-9 MAY 2007
HIKMA PHARMACEUTICALS PLC UBS GLOBAL GENERIC & SPECIALITY PHARMACEUTICALS CONFERENCE NEW YORK 8-9 MAY 2007 About Hikma Founded in Jordan in 1978 Multinational business developing, manufacturing and marketing
Notice of Annual General Meeting
Novartis AG To the holders of American Depositary Receipts (ADRs) of Novartis AG Notice of Annual General Meeting JPMorgan Chase Bank, N.A., the ADS depositary (the Depositary or JP Morgan ), has been
Danaher Corporation DHR [XNYS] QQQ
![Danaher Corporation DHR [XNYS] QQQ](/thumbs/77/76479167.jpg "Danaher Corporation DHR [XNYS] QQQ")
? Danaher Corporation DHR [XNYS] QQQ 5083 USD 5600 USD 3360 USD 8680 USD High Narrow A- Diversified Industrials Core Revenue Growth Continues to Weaken for Danaher in First Quarter by Daniel Holland Senior
Danaher Corporation DHR [XNYS] QQQ
![Danaher Corporation DHR [XNYS] QQQ](/thumbs/77/76479143.jpg "Danaher Corporation DHR [XNYS] QQQ")
? Danaher Corporation DHR [XNYS] QQQ Danaher's Third Quarter Below Expectations, Cash Flow Remains Strong by Daniel Holland Senior Stock Analyst Analyst covering this company do not own its stock. Pricing
CIF Stock Recommendation Report (Fall 2012)
Date: 10/11/12 Analyst Name: Joseph Brendel CIF Stock Recommendation Report (Fall 2012) Section (A) Summary Company Name and Ticker: Prudential (PRU) Recommendation Buy: No Target Price: 35 Sector: Financials
Ratios Current Industry Historical Median
[1] 51.90 Medical Devices Market Cap: 820 Mil Draegerwerk AG & Co KGaA provides medical and safety technology. The Company has two main divisions: safety division and medical division. It provides Fire
scr.zacks.com 111 North Canal Street, Chicago, IL (POZN-NASDAQ) UPDATE ZACKS ESTIMATES
Small-Cap Research November 25, 2013 Jason Napodano, CFA 312-265-9421 jnapodano@zacks.com scr.zacks.com 111 North Canal Street, Chicago, IL 60606 POZEN, Inc. (POZN-NASDAQ) POZN: Pozen To Distribute $1.75
About Deborah Wilkes
About Deborah Wilkes 25 years of reporting on the global OTC industry Co-founded OTC bulletin newsletter in 1993 Created UK OTC Marketing Awards Co-founded SourceOTC business development website in 2009
Last Earnings Release 10/17/2017. Last Qtr. Actual vs. Est. $1.85 / $1.80. Next Release 01/23/2018 $1.80. Year Ending 12/31/2016 $6.
Grade Earnings Last Earnings Release 10/17/2017 Last Qtr. Actual vs. Est. $1.85 / $1.80 Next Release 01/23/2018 $1.80 Year Ending 12/31/2016 $6.71 Quick Facts Dividend Yield 2.35% 52 Wk High $143.62 52
QCU and Exercises for Part 2 : 20 QCU (only one answer is right) and 1 Exercise. Session 4 : Shares Session 5 : Bonds. Corporate Finance.
QCU and Exercises for Part 2 : 20 QCU (only one answer is right) and 1 Exercise Session 4 : Shares Session 5 : Bonds Corporate Finance Master 1 2012-2013 All campuses 1 20 QCU Use the information for the
CIF Stock Recommendation Report (Fall 2012)
Date: 10/13/2012 Analyst Name: Ryan Ellingsen CIF Stock Recommendation Report (Fall 2012) Company Name and Ticker: Colgate-Palmolive Company (CL) Section (A) Summary Recommendation Buy: Hold Target Price:
CIF Stock Recommendation Report (Fall 2012)
Date: Saturday, November 10, 2012 Analyst Name: Fausto Guillén Aguilar Jr. CIF Stock Recommendation Report (Fall 2012) Company Name and Ticker: International Business Machines Corp IBM Section (A) Summary
May 2015 NASDAQ: HSKA Heska Corporation. All Rights Reserved.
May 2015 NASDAQ: HSKA 2015 Heska Corporation. All Rights Reserved. NASDAQ: HSKA Forward-Looking Statements This presentation may contain forward-looking statements within the meaning of the Private Securities
COMPETITIVE POSITIONING OF THE TOP 10 PLAYERS GROWING ALLIANCES IN BIOPHARMACEUTICALS TABLE 7 KEY LICENSING AND PARTNERSHIP DEALS IN
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 2 INTENDED AUDIENCE... 3 METHODOLOGY AND INFORMATION SOURCES... 3 ANALYST CREDENTIALS...
CIF Stock Recommendation Report (Spring 2014)
Date: 2/28/14 Analyst Name: Anthony Ledesma & Mason Yang CIF Stock Recommendation Report (Spring 2014) Company Name and Ticker: UnitedHealth Group (UNH) Section (A) Investment Summary Recommendation Buy:
Firepower fireworks. Focus, scale and growth drive explosive M&A. Firepower Index and Growth Gap Report 2015
January 2015 Perspectives from the EY Global Life Sciences Sector Firepower Index and Growth Gap Report 2015 Firepower fireworks Focus, scale and growth drive explosive M&A Biopharma M&A rockets to record
Basic Materials. Tim Stephenson Matthew Stewart November 8, 2016
Basic Materials Tim Stephenson Matthew Stewart November 8, 2016 - The sector consists of companies engaged in the discovery, development, and processing of raw materials MATERIALS INDUSTRY - AGENDA Agenda
M&A 2017 Review China Pharmaceutical Sector
www.pwccn.com M&A 217 Review China Pharmaceutical Sector April 218 Agenda Foreword Overview Strategic Buyers Financial Buyers Mainland China Outbound Deals 2 Foreword Explanation of data presented in this
Invesco V.I. Global Health Care Fund
Schedule of Investments (a) December 31, 2017 Shares Value Common Stocks & Other Equity Interests 94.97% Biotechnology 29.60% ACADIA Pharmaceuticals Inc. (b) 28,948 $ 871,624 Alexion Pharmaceuticals, Inc.
Annual report Putnam VT Global Health Care Fund
Putnam Variable Trust Annual report 12 31 17 Putnam VT Global Health Care Fund Message from the Trustees February 12, 2018 Dear Shareholder: We enter 2018 on the heels of an impressive year for global